{
  "docId": "019de075-4071-7657-953a-43c246cbe714",
  "docSlug": "684835678957e07d55af9fc01c6da54e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 44 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 44,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a navigation bar at the top to indicate the current section (Oncology).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4071-7657-953a-43c246cbe714/15",
  "deckHref": "/decks/019de075-4071-7657-953a-43c246cbe714",
  "deckJsonHref": "/decks/019de075-4071-7657-953a-43c246cbe714.json",
  "deckAnchorHref": "/decks/019de075-4071-7657-953a-43c246cbe714#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Oncology H1 2023 $8.8bn, +22%",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ae8659c-dcc1-4ab4-9fb5-91106af44253",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.45,
        "y": 0.23
      },
      "kind": "list",
      "text": "Q2 2023: key dynamics",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "460c1bed-2bc7-48c7-9d53-1ada354f7b73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "subtitle",
      "text": "All growth rates at CER. Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza). CER = constant exchange rates; NRDL = National Reimbursement Drug List; PS = Product Sales; EU = Europe; ERoW = Established Rest of World; EM = Emerging Markets; BTKi = bruton tyrosine kinase inhibitor; BRCAm = breast cancer gene mutation; CN = China; DB03 = DESTINY-Breast03; DB04 = DESTINY-Breast04.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f4cb8b5-8f97-4465-81e5-e177e4e82a20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Total Revenue +22% in H1 2023 fuelled by demand growth and launch momentum",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef9d7164-1e0e-40ae-b78f-7310dcf64713",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology – H1 and Q2 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc1c8707-cc94-43c4-aff5-08fcd47d8c13",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 9,
      "beatId": "1f13dd9d-adda-48c7-ad5c-4e44ba8f57d7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation showcases AstraZeneca's financial results, R&D highlights, and sustainability initiatives, providing a sense of satisfaction",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 5,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "8f711e18-1f16-4fa6-b2d7-b917fe429d2f",
      "evidence": "The presentation highlights multiple examples of AstraZeneca's growth and innovation across different disease areas",
      "position": 0,
      "objective": "To identify patterns and trends in AstraZeneca's growth and innovation",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}